39.53 USD
-0.37 (-0.93%)
39.53 USD
0 (0%)
Overall RPRX gets a fundamental rating of 6 out of 10. We evaluated RPRX against 192 industry peers in the Pharmaceuticals industry. While RPRX has a great profitability rating, there are some minor concerns on its financial health. RPRX may be a bit undervalued, certainly considering the very reasonable score on growth
1. Profitability
1.1 Basic Checks
In the past year RPRX was profitable.
RPRX had a positive operating cash flow in the past year.
RPRX had positive earnings in each of the past 5 years.
In the past 5 years RPRX always reported a positive cash flow from operatings.
1.2 Ratios
RPRX has a better Return On Assets (3.95%) than 84.90% of its industry peers.
The Return On Equity of RPRX (11.93%) is better than 86.98% of its industry peers.
RPRX's Return On Invested Capital of 6.43% is amongst the best of the industry. RPRX outperforms 84.38% of its industry peers.
RPRX had an Average Return On Invested Capital over the past 3 years of 5.98%. This is significantly below the industry average of 12.71%.
The last Return On Invested Capital (6.43%) for RPRX is above the 3 year average (5.98%), which is a sign of increasing profitability.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 3.95% | ||
| ROE | 11.93% | ||
| ROIC | 6.43% |
ROA(3y)3.97%
ROA(5y)3.7%
ROE(3y)10.17%
ROE(5y)10.3%
ROIC(3y)5.98%
ROIC(5y)6.56%
1.3 Margins
Looking at the Profit Margin, with a value of 32.55%, RPRX belongs to the top of the industry, outperforming 95.83% of the companies in the same industry.
In the last couple of years the Profit Margin of RPRX has declined.
RPRX has a better Operating Margin (65.22%) than 100.00% of its industry peers.
In the last couple of years the Operating Margin of RPRX has declined.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 65.22% | ||
| PM (TTM) | 32.55% | ||
| GM | N/A |
OM growth 3Y-2.96%
OM growth 5Y-16.96%
PM growth 3Y11.92%
PM growth 5Y-21.76%
GM growth 3YN/A
GM growth 5YN/A
2. Health
2.1 Basic Checks
With a Return on Invested Capital (ROIC) below the Cost of Capital (WACC), RPRX is destroying value.
RPRX has less shares outstanding than it did 1 year ago.
Compared to 5 years ago, RPRX has more shares outstanding
RPRX has a worse debt/assets ratio than last year.
2.2 Solvency
RPRX has an Altman-Z score of 1.69. This is a bad value and indicates that RPRX is not financially healthy and even has some risk of bankruptcy.
RPRX has a Altman-Z score of 1.69. This is comparable to the rest of the industry: RPRX outperforms 58.33% of its industry peers.
RPRX has a debt to FCF ratio of 9.47. This is a negative value and a sign of low solvency as RPRX would need 9.47 years to pay back of all of its debts.
Looking at the Debt to FCF ratio, with a value of 9.47, RPRX is in the better half of the industry, outperforming 78.13% of the companies in the same industry.
A Debt/Equity ratio of 1.34 is on the high side and indicates that RPRX has dependencies on debt financing.
With a Debt to Equity ratio value of 1.34, RPRX is not doing good in the industry: 76.04% of the companies in the same industry are doing better.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 1.34 | ||
| Debt/FCF | 9.47 | ||
| Altman-Z | 1.69 |
ROIC/WACC0.78
WACC8.29%
2.3 Liquidity
RPRX has a Current Ratio of 3.48. This indicates that RPRX is financially healthy and has no problem in meeting its short term obligations.
RPRX has a Current ratio of 3.48. This is comparable to the rest of the industry: RPRX outperforms 54.17% of its industry peers.
A Quick Ratio of 3.48 indicates that RPRX has no problem at all paying its short term obligations.
Looking at the Quick ratio, with a value of 3.48, RPRX is in line with its industry, outperforming 55.73% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 3.48 | ||
| Quick Ratio | 3.48 |
3. Growth
3.1 Past
RPRX shows a small growth in Earnings Per Share. In the last year, the EPS has grown by 0.24%.
Measured over the past years, RPRX shows a very negative growth in Earnings Per Share. The EPS has been decreasing by -18.23% on average per year.
RPRX shows a small growth in Revenue. In the last year, the Revenue has grown by 3.70%.
The Revenue has been growing slightly by 4.52% on average over the past years.
EPS 1Y (TTM)0.24%
EPS 3Y22.51%
EPS 5Y-18.23%
EPS Q2Q%15.84%
Revenue 1Y (TTM)3.7%
Revenue growth 3Y-0.38%
Revenue growth 5Y4.52%
Sales Q2Q%44.07%
3.2 Future
Based on estimates for the next years, RPRX will show a quite strong growth in Earnings Per Share. The EPS will grow by 12.58% on average per year.
Based on estimates for the next years, RPRX will show a quite strong growth in Revenue. The Revenue will grow by 10.36% on average per year.
EPS Next Y11.77%
EPS Next 2Y11.15%
EPS Next 3Y11.71%
EPS Next 5Y12.58%
Revenue Next Year14.96%
Revenue Next 2Y8.31%
Revenue Next 3Y7.87%
Revenue Next 5Y10.36%
3.3 Evolution
When comparing the EPS growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
4. Valuation
4.1 Price/Earnings Ratio
The Price/Earnings ratio is 9.62, which indicates a very decent valuation of RPRX.
Based on the Price/Earnings ratio, RPRX is valued cheaper than 91.67% of the companies in the same industry.
Compared to an average S&P500 Price/Earnings ratio of 26.15, RPRX is valued rather cheaply.
The Price/Forward Earnings ratio is 7.80, which indicates a rather cheap valuation of RPRX.
RPRX's Price/Forward Earnings ratio is rather cheap when compared to the industry. RPRX is cheaper than 91.15% of the companies in the same industry.
The average S&P500 Price/Forward Earnings ratio is at 36.22. RPRX is valued rather cheaply when compared to this.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 9.62 | ||
| Fwd PE | 7.8 |
4.2 Price Multiples
Based on the Price/Free Cash Flow ratio, RPRX is valued cheaply inside the industry as 82.29% of the companies are valued more expensively.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 24.15 | ||
| EV/EBITDA | N/A |
4.3 Compensation for Growth
The low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.
The decent profitability rating of RPRX may justify a higher PE ratio.
PEG (NY)0.82
PEG (5Y)N/A
EPS Next 2Y11.15%
EPS Next 3Y11.71%
5. Dividend
5.1 Amount
RPRX has a Yearly Dividend Yield of 2.21%. Purely for dividend investing, there may be better candidates out there.
Compared to an average industry Dividend Yield of 6.81, RPRX pays a better dividend. On top of this RPRX pays more dividend than 93.23% of the companies listed in the same industry.
RPRX's Dividend Yield is comparable with the S&P500 average which is at 2.32.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 2.21% |
5.2 History
RPRX has been paying a dividend for over 5 years, so it has already some track record.
RPRX has not decreased its dividend in the last 3 years.
Dividend Growth(5Y)N/A
Div Incr Years4
Div Non Decr Years4
5.3 Sustainability
RPRX pays out 49.36% of its income as dividend. This is a bit on the high side, but may be sustainable.
DP49.36%
EPS Next 2Y11.15%
EPS Next 3Y11.71%
39.53
-0.37 (-0.93%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)
Earnings (Next)
Inst Owners82.15%
Inst Owner Change-2.77%
Ins Owners1.79%
Ins Owner Change9.31%
Market Cap22.82B
Revenue(TTM)2.35B
Net Income(TTM)764.96M
Analysts82.67
Price Target46 (16.37%)
Short Float %6.19%
Short Ratio6.45
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 2.21% |
Yearly Dividend0.63
Dividend Growth(5Y)N/A
DP49.36%
Div Incr Years4
Div Non Decr Years4
Ex-Date
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)6.5%
Min EPS beat(2)3.01%
Max EPS beat(2)9.99%
EPS beat(4)3
Avg EPS beat(4)-10%
Min EPS beat(4)-59.9%
Max EPS beat(4)9.99%
EPS beat(8)5
Avg EPS beat(8)-3.29%
EPS beat(12)9
Avg EPS beat(12)0.42%
EPS beat(16)10
Avg EPS beat(16)-0.98%
Revenue beat(2)2
Avg Revenue beat(2)6.07%
Min Revenue beat(2)4.2%
Max Revenue beat(2)7.95%
Revenue beat(4)3
Avg Revenue beat(4)1.88%
Min Revenue beat(4)-14.22%
Max Revenue beat(4)9.61%
Revenue beat(8)3
Avg Revenue beat(8)-6.2%
Revenue beat(12)3
Avg Revenue beat(12)-10.78%
Revenue beat(16)4
Avg Revenue beat(16)-8.96%
PT rev (1m)3.8%
PT rev (3m)4.2%
EPS NQ rev (1m)2.11%
EPS NQ rev (3m)1.92%
EPS NY rev (1m)0.13%
EPS NY rev (3m)-0.2%
Revenue NQ rev (1m)4.57%
Revenue NQ rev (3m)1.48%
Revenue NY rev (1m)0.78%
Revenue NY rev (3m)1.78%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 9.62 | ||
| Fwd PE | 7.8 | ||
| P/S | 9.71 | ||
| P/FCF | 24.15 | ||
| P/OCF | 9.49 | ||
| P/B | 3.56 | ||
| P/tB | 4.16 | ||
| EV/EBITDA | N/A |
EPS(TTM)4.11
EY10.4%
EPS(NY)5.07
Fwd EY12.81%
FCF(TTM)1.64
FCFY4.14%
OCF(TTM)4.17
OCFY10.54%
SpS4.07
BVpS11.11
TBVpS9.51
PEG (NY)0.82
PEG (5Y)N/A
Graham Number32.06
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 3.95% | ||
| ROE | 11.93% | ||
| ROCE | 8.15% | ||
| ROIC | 6.43% | ||
| ROICexc | 7.12% | ||
| ROICexgc | 7.53% | ||
| OM | 65.22% | ||
| PM (TTM) | 32.55% | ||
| GM | N/A | ||
| FCFM | 40.2% |
ROA(3y)3.97%
ROA(5y)3.7%
ROE(3y)10.17%
ROE(5y)10.3%
ROIC(3y)5.98%
ROIC(5y)6.56%
ROICexc(3y)6.7%
ROICexc(5y)7.58%
ROICexgc(3y)6.7%
ROICexgc(5y)7.59%
ROCE(3y)7.57%
ROCE(5y)8.31%
ROICexgc growth 3Y-4.76%
ROICexgc growth 5Y-18.24%
ROICexc growth 3Y-4.74%
ROICexc growth 5Y-18.16%
OM growth 3Y-2.96%
OM growth 5Y-16.96%
PM growth 3Y11.92%
PM growth 5Y-21.76%
GM growth 3YN/A
GM growth 5YN/A
F-Score5
Asset Turnover0.12
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 1.34 | ||
| Debt/FCF | 9.47 | ||
| Debt/EBITDA | N/A | ||
| Cap/Depr | N/A | ||
| Cap/Sales | 62.15% | ||
| Interest Coverage | -5.67 | ||
| Cash Conversion | N/A | ||
| Profit Quality | 123.5% | ||
| Current Ratio | 3.48 | ||
| Quick Ratio | 3.48 | ||
| Altman-Z | 1.69 |
F-Score5
WACC8.29%
ROIC/WACC0.78
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)92.8%
Cap/Sales(5y)95.39%
Profit Quality(3y)349.23%
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)0.24%
EPS 3Y22.51%
EPS 5Y-18.23%
EPS Q2Q%15.84%
EPS Next Y11.77%
EPS Next 2Y11.15%
EPS Next 3Y11.71%
EPS Next 5Y12.58%
Revenue 1Y (TTM)3.7%
Revenue growth 3Y-0.38%
Revenue growth 5Y4.52%
Sales Q2Q%44.07%
Revenue Next Year14.96%
Revenue Next 2Y8.31%
Revenue Next 3Y7.87%
Revenue Next 5Y10.36%
EBIT growth 1Y-0.72%
EBIT growth 3Y-3.33%
EBIT growth 5Y-13.2%
EBIT Next Year28.89%
EBIT Next 3Y14.6%
EBIT Next 5Y13.57%
FCF growth 1Y-33.55%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-13.64%
OCF growth 3Y11.13%
OCF growth 5Y10.68%
ROYALTY PHARMA PLC- CL A / RPRX FAQ
Can you provide the ChartMill fundamental rating for ROYALTY PHARMA PLC- CL A?
ChartMill assigns a fundamental rating of 6 / 10 to RPRX.
What is the valuation status of ROYALTY PHARMA PLC- CL A (RPRX) stock?
ChartMill assigns a valuation rating of 8 / 10 to ROYALTY PHARMA PLC- CL A (RPRX). This can be considered as Undervalued.
Can you provide the profitability details for ROYALTY PHARMA PLC- CL A?
ROYALTY PHARMA PLC- CL A (RPRX) has a profitability rating of 7 / 10.
Can you provide the PE and PB ratios for RPRX stock?
The Price/Earnings (PE) ratio for ROYALTY PHARMA PLC- CL A (RPRX) is 9.62 and the Price/Book (PB) ratio is 3.56.
Is the dividend of ROYALTY PHARMA PLC- CL A sustainable?
The dividend rating of ROYALTY PHARMA PLC- CL A (RPRX) is 4 / 10 and the dividend payout ratio is 49.36%.